Grünenthal GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1946-01-01

Employees: 1K

Market Cap: -

Website: http://www.grunenthal.com

Clinical Trials

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

Phase 3

Terminated

Conditions: Osteoarthritis
Chronic Pain

Interventions: Drug: Tapentadol PR

First Posted Date: 2009-09-23

Last Posted Date: 2019-10-18

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 82

Registration Number: NCT00982280

Locations: 🇵🇱
Site 5, Ostrow Mazowiecka, Poland
🇬🇧
Site 6, Carmarthen, United Kingdom
🇪🇸
Site 4, Madrid, Spain

and more 7 locations

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic

Phase 3

Completed

Conditions: Chronic Pain
Osteoarthritis

Interventions: Drug: Tapentadol

First Posted Date: 2009-09-23

Last Posted Date: 2019-10-21

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 224

Registration Number: NCT00983073

Locations: 🇬🇧
Site 1, Solihull, United Kingdom
🇪🇸
Site 2, A Coruna, Spain
🇬🇧
Site 4, Swansea, United Kingdom

and more 8 locations

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Phase 3

Completed

Conditions: Bunionectomy
Pain
Postoperative Pain
Acute Pain

Interventions: Drug: Placebo
Drug: CG5503 IR
Drug: Morphine

First Posted Date: 2008-02-07

Last Posted Date: 2011-11-16

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 291

Registration Number: NCT00609466

Locations: 🇺🇸
Site 103, San Marcos, Texas, United States
🇺🇸
Site 105, San Antonio, Texas, United States
🇺🇸
Site 104, Pasadena, Maryland, United States

and more 3 locations

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Phase 3

Terminated

Conditions: Pain
Neoplasm
Cancer

Interventions: Drug: Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase
Drug: Morphine in the Maintenance Phase
Drug: Tapentadol in the Titration Phase
Drug: Morphine in the Titration Phase
Drug: Tapentadol in the Maintenance Phase

First Posted Date: 2007-07-23

Last Posted Date: 2019-11-01

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 136

Registration Number: NCT00505414

Locations: 🇦🇷
054003, La Plata, Buenos Aires, Argentina
🇦🇷
054012, Pergamino, Buenos Aires, Argentina
🇦🇷
054015, Santa Fe, Argentina

and more 34 locations

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Phase 3

Completed

Conditions: Pain
Knee Osteoarthritis

Interventions: Drug: Tapentadol ER (100 to 250 mg twice daily)
Drug: Matching Placebo (twice daily)
Drug: Oxycodone CR (20 to 50 mg twice daily)

First Posted Date: 2007-06-15

Last Posted Date: 2019-10-18

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 990

Registration Number: NCT00486811

Locations: 🇦🇹
Site 043002, Salzburg, Austria
🇭🇷
Site 385002, Zagreb, Croatia
🇦🇹
Site 043006, Mitterdorf, Austria

and more 97 locations

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Phase 3

Completed

Conditions: Hysterectomy
Postoperative

Interventions: Drug: CG5503 IR
Drug: Placebo
Drug: Morphine

First Posted Date: 2007-05-24

Last Posted Date: 2019-10-28

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 854

Registration Number: NCT00478023

Locations: 🇷🇺
Site 44, Moscow, Russian Federation
🇸🇰
Site 52, Bratislava, Slovakia
🇸🇰
Site 62, Kosice, Slovakia

and more 49 locations

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Phase 3

Completed

Conditions: Tumor
Pain

Interventions: Drug: Tapentadol Extended Release
Drug: Morphine Sulphate Controlled Release
Drug: Matching Placebo after Tapentadol in the Titration Phase.

First Posted Date: 2007-05-11

Last Posted Date: 2019-11-04

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 622

Registration Number: NCT00472303

Locations: 🇩🇪
Site 049014, Essen, Germany
🇭🇺
Site 036003, Mátraháza, Hungary
🇷🇴
Site 040003, Bucharest, Romania

and more 68 locations

Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)

Phase 1

Terminated

Conditions: Healthy

First Posted Date: 2007-05-04

Last Posted Date: 2007-11-16

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 36

Registration Number: NCT00469053

Locations: 🇩🇪
Site Mannheim, Mannheim, Germany

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)

Phase 1

Terminated

Conditions: Healthy

First Posted Date: 2007-05-04

Last Posted Date: 2007-11-16

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 24

Registration Number: NCT00469404

Locations: 🇩🇪
Site Mannheim, Mannheim, Germany

Bioequivalence Trial of a New Opioid Combination Compared to Reference

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-04-16

Last Posted Date: 2007-07-06

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 32

Registration Number: NCT00460785

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy